Table 2.

Comparison of the patients who were given tocilizumab based on the severity of cases.

	Tocilizumab in severe cases N = 21 (%)	Tocilizumab in critical cases N = 22 (%)	p
Mean age	61 (sd: 15)	66 (sd: 11)	0.198
Male gender	11 (52)	20 (91)	0.005
Confirmed COVID-19	17 (81)	18 (82)	0.9
Hypertension	9 (43)	10 (45)	0.864
Diabetes mellitus	7 (33)	6 (27)	0.665
Obesity	3 (14)	2 (9)	0.595
Chronic obstructive pulmonary disease	2 (10)	1 (5)	0.522
Coronary artery disease	6 (29)	2 (9)	0.101
Laboratory (on the day of TCZ) (median, min–max)
CRP (mg/L)	88 (1–299)	233 (25–380)	0.0029
Ferritin (ng/mL)	575 (273–1991)	1884 (250–52,765)	0.008
D-Dimer (μg/L)	870 (360–2300)	1710 (620–100,000)	0.002
IL-6 (pg/mL)	115 (18–942)	168 (27–50,000)	0.025
ALT (U/L)	78 (14–428)	58 (17–1578)	0.796
AST (U/L)	58 (27–129)	64 (24–2045)	0.354
LDH (U/L))	358 (205–544)	381 (197–5770)	0.183
Procalcitonin (ng/mL)	0.15 (0.04–0.44)	0.38 (0.07–100)	0.001
Leucocyte (K/μL)	6.38 (2.25–9.6)	7.98 (1.74–19.1)	0.96
Lymphocyte (%)	13.5 (7–47)	11 (3–26)	0.007
Platelet (K/μL)	242 (62–582)	227 (97–473)	0.52
Clinical support
Oxygen support duration before tocilizumab (days)	1 (0–7)	4 (1–13)	<0.001
Duration from onset of symptoms to tocilizumab (days)	9.5 (5–18)	10 (5–26)	0.76
Favipiravir	15 (71)	19 (86)	0.23
Hydroxychloroquine	18 (86)	20 (91)	0.6
Azithromycin	14 (67)	11 (50)	0.27
Lopinavir/Ritonavir	0	7 (32)	0.005
Outcomes
Duration of oxygen support after tocilizumab	5 (0–16)	12 (6–30)	<0.001
Length of stay after tocilizumab (days)	7.5 (2–21)	12 (4–30)	0.028
Length of stay	12.5 (6–32)	20 (8–43)	0.009
Secondary bacterial infection	–	9 (41)	0.001
Pneumonia	–	6 (27.3)	0.01
Corynebacterium spp.	–	4
Bacteremia	–	5 (22.7)	0.02
Fatal	0 (0)	6 (27)	0.01

Abbreviations: CRP, C-reactive protein; IL-6, interleukin-6; AST, aspartate transaminase; ALT, alanine transaminase; LDH, lactate dehydrogenase.